← 返回前沿论文

γδ T 细胞亚群中检查点受体的动态变化与抗 PD-1 免疫治疗期间的临床反应相关

英文原题:Dynamics of checkpoint receptors in γδ T cell subsets are associated with clinical response during anti-PD-1 immunotherapies.

查看英文原题

Dynamics of checkpoint receptors in γδ T cell subsets are associated with clinical response during anti-PD-1 immunotherapies.

PubMed 2025/11/27(内容时间) EMBO Mol Med Q1 · IF 7.9(JCR 2025)

研究概要

我们的数据表明ICR与γδ T细胞之间存在复杂的相互关系,并揭示了利用这些细胞以辨别或改进癌症免疫治疗的新方法。

中文摘要

γδ T 细胞是具有强效抗肿瘤特性的固有样淋巴细胞。在此,我们表明免疫检查点受体(ICR)在 Vδ1 和 Vδ2 细胞中表现出差异性表达并受 JAK-STAT 通路调控,并鉴定了组成性(如 TIGIT、PD-1)和诱导性(如 TIM-3、LAG-3、CTLA-4)ICR。在黑色素瘤中,所有 γδ T 细胞亚群均下调 AP-1 转录因子,但 Vδ1 细胞特异性表达高水平 ICR、TOX 和抑制性杀伤细胞 Ig 样受体(KIR)转录本, reminiscent of exhaustion。然而,患者来源的细胞在功能上具有能力,尽管 LAG-3 和 CTLA-4 的诱导受损。在抗 PD-1 单药治疗期间,Vδ1 细胞特异性结合高水平治疗性抗体,但仅在治疗应答的患者中,揭示了用于评估 IC 阻断(ICB)治疗疗效的潜在新预后标志物。最后,在成功的 ICB 治疗应答中,Vδ1 细胞中 KIR 基因的表达下调。总之,我们的数据表明 ICR 与 γδ T 细胞之间存在复杂关系,并揭示了利用这些细胞以辨别或改善癌症免疫治疗的新方法。

展开英文摘要原文

Gamma delta (γδ) T cells are innate-like lymphocytes with potent anti-tumor properties. Herein, we show that immune checkpoint receptors (ICRs) display differential expression and regulation by the JAK-STAT pathway in Vδ1 and Vδ2 cells and identify constitutive (e.g. TIGIT, PD-1) and inducible (e.g. TIM-3, LAG-3, CTLA-4) ICRs. In melanoma, all γδ T cell subsets downregulated AP-1 transcription factors, but Vδ1 cells specifically expressed high levels of ICR, TOX and inhibitory killer Ig-like receptor (KIR) transcripts, reminiscent of exhaustion. However, patient-derived cells were functionally competent, although induction of LAG-3 and CTLA-4 was impaired. During anti-PD-1 monotherapy, Vδ1 cells specifically bound high levels of therapeutic antibody but only in patients who responded to treatment, revealing a potential new prognostic marker for evaluating the efficacy of IC blockade (ICB) therapy. Finally, expression of KIR genes in Vδ1 cells was downregulated in response to successful ICB therapy. Collectively, our data indicate an intricate relationship between ICRs and γδ T cells and reveal novel approaches by which these cells can be harnessed in order to discern or improve cancer immunotherapy.

论文信息

作者
Catafal-Tardos E、Dachicourt L、Baglioni MV、Fares da Silva MGF、Secci D、Donia M、Kverneland AH、Svane IM
第一作者单位
Department of Health Technology, Technical University of Denmark, Kgs Lyngby, Denmark.Denmark
通讯作者单位
Department of Health Technology, Technical University of Denmark, Kgs Lyngby, Denmark. vasbek@dtu.dk.Denmark
期刊
EMBO molecular medicine2026 Jan
原文标识
PubMed 41310392 · DOI 10.1038/s44321-025-00338-9